In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide.
Ji, Y., Majumder, S., Millard, M., Borra, R., Bi, T., Elnagar, A.Y., Neamati, N., Shekhtman, A., Camarero, J.A.(2013) J Am Chem Soc 135: 11623-11633
- PubMed: 23848581 
- DOI: 10.1021/ja405108p
- Primary Citation of Related Structures:  
2M86 - PubMed Abstract: 
The overexpression of Hdm2 and HdmX is a common mechanism used by many tumor cells to inactive the p53 tumor suppressor pathway promoting cell survival. Targeting Hdm2 and HdmX has emerged as a validated therapeutic strategy for treating cancers with wild-type p53 ...